Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program ; volume:19 ; number:1 ; day:7 ; month:1 ; year:2019 ; pages:1-10 ; date:12.2019
BMC cancer ; 19, Heft 1 (7.1.2019), 1-10, 12.2019
- Creator
-
Heidenreich, Axel
Gillessen, Silke
Heinrich, Daniel
Keizman, Daniel
O’Sullivan, Joe M.
Carles, Joan
Wirth, Manfred
Miller, Kurt
Reeves, John
Seger, Monica
Nilsson, Sten
Saad, Fred
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-018-5203-y
- URN
-
urn:nbn:de:101:1-2019022008051211571107
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Heidenreich, Axel
- Gillessen, Silke
- Heinrich, Daniel
- Keizman, Daniel
- O’Sullivan, Joe M.
- Carles, Joan
- Wirth, Manfred
- Miller, Kurt
- Reeves, John
- Seger, Monica
- Nilsson, Sten
- Saad, Fred
- SpringerLink (Online service)
Other Objects (12)
Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases
Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223
Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223
Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases
Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223
Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223
Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases
Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223